rocky start for alzheimers research
Last Updated : GMT 06:49:16
Arab Today, arab today
Arab Today, arab today
Last Updated : GMT 06:49:16
Arab Today, arab today

in 2018

Rocky start for Alzheimer's research

Arab Today, arab today

Arab Today, arab today Rocky start for Alzheimer's research

Designer Guio Di Colombia in Inclusion fashion show in Colombia.
Paris - Arab Today

The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Within the first three weeks, pharmaceutical giant Pfizer abandoned the costly and frustrating field of dementia drug development, and two promising treatments stumbled in patient trials.

Alzheimer's support groups are putting on a brave face, but the collective disappointment is palpable as the global cost of caring for some 50 million dementia sufferers is set to reach $1 trillion (819 billion euros) this year.

"It's very fair to say that progress is slow," David Reynolds, chief scientific officer at Alzheimer's Research UK, a charity, told AFP.

"Companies have put a lot of time, effort and money in over the last 25 years, and there haven't been any new medicines launched in this area for 16 years now."

Experts say it takes 12–15 years, on average, and more than $2 billion to develop a single drug.

According to the Alzforum website, which gathers data on candidate drugs, fewer than 300 have made it to Phase II drug efficiency trials so far.

Only five have ever been approved to treat symptoms such as memory loss associated with Alzheimer's, first identified more than 100 years ago.

With a clinical trial failure rate of over 99 percent, there is still no licenced drug that slows the condition's progression, or cures it.

Today, about 100 candidate dementia drugs are enrolled in trials, compared to over 1,000 for cancer, according to Reynolds.

One reason is that "pharmaceutical companies ultimately are companies. They are beholden to their investors," he said.

"A return on investment is really: How much time and money do you put into getting a new medicine versus how much money can you make once you've actually got it? In this area, success has been very difficult to come by."

- Mysterious brain -

The stakes are high.

According to the World Health Organization (WHO), some 10 million people per year are diagnosed with dementia, with Alzheimer's disease accounting for about two-thirds of cases.

By 2030, the number of sufferers is projected to reach 82 million globally, and by 2050 some 152 million.

The medical, patient-care, and economic costs are enormous.

A heavy burden falls on family members, the majority of care providers worldwide. Many have to give up their jobs.

Alzheimer's affects mainly older people -- about one in four over-85s is a sufferer. And numbers have soared as lifespans have lengthened thanks to medical advances in other fields.

With cardiovascular disease and cancer the biggest killers in the 1960s and '70s, that is where most of the research money went.

"In dementia, that investment wasn't there. So the amount of knowledge... about the disease is at a much, much earlier stage, and arguably the brain is a much more complicated organ" than the heart, said Reynolds.

To this day, scientists don't know exactly what causes Alzheimer's, leaving drug developers stumped.

On January 6, Pfizer announced an end to its "discovery and early development efforts" for Alzheimer's and Parkinson's dementia drugs.

Two days later, Danish company Lundbeck reported its idalopirdine compound did not "decrease cognitive loss" in patients, and on January 12, biotech firm Axovant announced the end of the road for its offering, intepirdine.

- Slow, but not backwards -

Experts say every failure of a drug reveals something new about Alzheimer's disease, which is thought to be associated with a buildup of protein "plaques", and "tangles" in the brain.

One important recent realisation was that an effective treatment may have to begin long before symptoms appear as protein build-up likely starts decades before disease sets in.

This, in itself, presents a research challenge.

"How do you find these patients?" when they are in middle age and symptom-free, explained French neurology professor Bruno Dubois. "How long do you treat them?"

Drugs in development today are targeting several tracks.

Some use antibodies to mop up proteins in circulation, or enzymes to inhibit their production.

Another experimental approach is vaccination: training the body to produce its own antibodies to attack disease-causing proteins.

"We are not moving backwards," insisted Reynolds.

Yet, he was "by no means certain" that a goal set by the G8 in 2013 to develop a cure or treatment for dementia by 2025 can be met.

"Even knowing the obstacles, we have never been as optimistic as we are today," added James Hendrix, a director at the US-based Alzheimer's Association, one of several non-profit research funders.

"We will not slow down in our fight against this terrible disease," he vowed.

"We are steadfastly committed to both advocating for further increased federal funding for Alzheimer's and dementia research, and increasing our own level of research funding to get us to where we ultimately need to be -- a world without Alzheimer's disease."

Source: AFP

 

arabstoday
arabstoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

rocky start for alzheimers research rocky start for alzheimers research

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

rocky start for alzheimers research rocky start for alzheimers research

 



GMT 08:17 2016 Wednesday ,24 August

Turkey launches anti-Daesh operation in Syria

GMT 18:08 2017 Sunday ,10 December

Bahrain arrests Iranian-backed terror suspect

GMT 16:58 2017 Friday ,06 January

DFWAC discusses women and children's protection

GMT 05:21 2017 Wednesday ,09 August

New China Premier Pledges Strong Ties with US

GMT 15:32 2017 Friday ,20 January

Obelix is the star of new Asterix adventure

GMT 00:03 2017 Tuesday ,02 May

HM King congratulates Dutch, Swedish kings

GMT 07:10 2017 Monday ,23 October

Italy regions back 'big bang' autonomy

GMT 21:23 2017 Saturday ,29 April

Daily News Bulletin

GMT 20:57 2017 Saturday ,11 February

FM meets US Congress delegation

GMT 05:51 2017 Sunday ,22 October

Centrepoint’s Autumn/Winter ’17

GMT 09:57 2018 Wednesday ,10 January

Future bloc: We are waiting for Hariri's return

GMT 07:26 2017 Tuesday ,19 December

EU demands extra effort

GMT 09:44 2017 Monday ,18 December

Worker in British embassy Found Strangled in Lebanon

GMT 15:03 2017 Saturday ,29 April

4 militants killed in eastern Algeria

GMT 14:38 2011 Friday ,25 November

Queen award for University

GMT 09:47 2017 Monday ,11 December

Amal Rizk happy for participating in new show

GMT 06:19 2017 Thursday ,19 October

Arab Monetary Fund, OECD sign MoU to boost cooperation

GMT 11:26 2017 Sunday ,23 April

US Supercarrier to Arrive in Sea of Japan
Arab Today, arab today
 
 Arab Today Facebook,arab today facebook  Arab Today Twitter,arab today twitter Arab Today Rss,arab today rss  Arab Today Youtube,arab today youtube  Arab Today Youtube,arab today youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

arabstoday arabstoday arabstoday arabstoday
arabstoday arabstoday arabstoday
arabstoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
arabstoday, Arabstoday, Arabstoday